Blood micro-RNA colorectal cancer diagnosis molecule combination

A colorectal cancer, molecular technology, applied in analytical materials, measuring devices, instruments, etc., can solve the problems of limited clinical application and promotion, achieve reliable clinical feasibility and practicability, reduce false positives and false negatives, and high population specificity. sexual effect

Inactive Publication Date: 2017-07-14
SHANGHAI TENTH PEOPLES HOSPITAL
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is also worth noting that, as a non-invasive blood diagnostic marker, how miRNA integrates with traditional clinical markers is still unknown, which greatly limits its clinical application (Cekaite L, Eide PW, Lind GE, Skotheim RI, Lothe RA, et al., MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2016 7(6):6476-50)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood micro-RNA colorectal cancer diagnosis molecule combination
  • Blood micro-RNA colorectal cancer diagnosis molecule combination
  • Blood micro-RNA colorectal cancer diagnosis molecule combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] In the present invention, first, the present invention designed a multi-stage, two-center, case-control study for identifying colorectal cancer-specific plasma microRNA markers. Mainly through the systematic evaluation of candidate miRNA diagnostic markers, and then using the high sensitivity of qRT-PCR detection, from the candidate marker molecules, the differences between colorectal cancer patients and healthy volunteers in cohort 1 were initially analyzed. sieve (such as figure 1 , 3). On this basis, expand the sample size, and verify between colorectal cancer patients and healthy volunteers in different cohort 2 from the differential microRNA obtained in the primary screening (such as figure 2 , 4).

[0033] The clinical value of the 9 miRNAs tested in Table 2 in the diagnosis of colorectal cancer

[0034]

[0035]

[0036] It can be seen from Table 2 that all the nine miRNA molecular markers involved in the present invention can clearly distinguish color...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a blood micro-RNA colorectal cancer diagnosis molecule combination including one or more selected from: hsa-miR-15b, hsa-miR-17, hsa-miR-19a, hsa-miR-21, hsa-miR-24, hsa-miR-26b, hsa-miR-145, hsa-miR-592 and hsa-miR-760. An optimum combination of a micro-RNA biomarker is designed by analyzing the markers hereinabove and is used as a biomarker detection model for the colorectal cancer. Especially, the invention relates to two micro-RNA markers, hsa-miR-17 and hsa-miR-26b, which have specificity and fetal origins of the colorectal cancer, wherein the hsa-miR-26b can be used for evaluating differentiated degree, lesion position and tumor burden of the colorectal cancer.

Description

technical field [0001] The invention relates to a tumor-specific nucleic acid molecular diagnostic marker, in particular to a combination of blood micronucleic acid (microRNA) colorectal cancer diagnostic molecules. Background technique [0002] Colorectal cancer is a common malignant tumor of the digestive system in my country. In 2015, the number of cases was about 376,300, and the number of deaths was about 191,000. It ranks among the five most common malignant tumors. With the improvement of diagnosis and treatment measures, the prognosis of patients with early colorectal cancer has improved significantly, and the five-year survival rate of stage I patients has exceeded 90%. However, the five-year survival rate plummets to 8.1% when the tumor progresses to stage IV. Therefore, early diagnosis can significantly prolong the survival period of patients, and is an important entry point for the prevention and treatment of colorectal cancer. At present, the following methods...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/574G01N33/57446G01N33/57473G01N33/57484
Inventor 秦环龙潘成
Owner SHANGHAI TENTH PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap